Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
IBRANCE® (palbociclib) + an AI | Preplanned PFS Analyses | Safety Info
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer | PLOS ONE
Clinical Trial Summary | IBRANCE® (palbociclib) | Safety Info
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up | SpringerLink
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent. - ppt download
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent. - ppt download
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...
Endocrine Combinations in HR-Positive MBC: The Future Is Now - ppt download
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Are all cyclin-dependent kinases 4/6 inhibitors created equal? | npj Breast Cancer
Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2 - The Breast
Progression-free survival in the PALOMA-1 study (palbociclib +... | Download Scientific Diagram
Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies - European Journal of Cancer
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent. - ppt download
Palbociclib in ER+ Breast Cancer - Breast Cancer - 2016 American Society of Clinical Oncology Annual Meeting - Oncology - Clinical Care Options
